Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.
The Optum EHR database was current up to 30-Jun-2020.
Identification period: From 01-Apr-2007 to 30-Jun-2019
Study period: From 01-Jan-2007 to 30-Jun-2020
Index date:
First evidence of resistance to or intolerance of HU treatment in patients with PV according to modified European Leukemia Net (ELN) criteria and defined as:
Pre-index period:
Patients had a minimum of 3 months pre-index data available. Pre-index data availability was determined using the reported 'first month active' field.
Post-index period:
There was no minimum post-index period required. Each patient had a 'first month active' and 'last month active' reported within the database. As the 'last month active' was based on any activity in the database, including encounters such as letters and emails which occurred several months after the 'death_date' of the patient, using the 'last month active' can overestimate the follow-up for a given patient. For this reason, the end of follow-up for each patient was defined as the date of the last activity within the diagnosis, observations, prescriptions, laboratories, procedures tables or discharge date from the last visit within the visit table (whichever of these activities occurs latest). This underestimated the follow-up for some patients where they were not actively using healthcare resources.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ruxolitinib (RUX) | PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period. |
| |
| Best available therapy (BAT) | PV patients who were resistant to or intolerant of Hydroxyurea (HU) (as defined on the index date) and continued HU treatment or switched to other available therapies other than RUX in the post-index period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ruxolitinib | Other | PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Thromboembolic events between the RUX and BAT group | Thromboembolic events in overall Polycythemia Vera cohort and in the BAT and RUX groups were reported. A TE was defined using International Classification of Diseases 9th Revision (ICD-9- CM) and International Classification of Diseases 10th Revision (ICD-10-CM) codes previously curated as restrictive (RESPONSE RCT) and extensive (GEMFIN) definitions of TE's within the Diagnosis table in Optum EHR database. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Number of Thromboembolic events between the high and low risk subgroups of BAT group | Within the BAT group, high risk (≥ 1 TE on average per year ) and low risk (< 1 TE on average per year) subgroups were identified based on the frequency of TEs and characterized according to patient sociodemographics, comorbidities, symptoms, clinical, and medication variables. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence rate of thromboembolic event | Difference in the incidence rate of TEs in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX were reported. A TE was defined using International Classification of Diseases 9th Revision (ICD-9- CM) and International Classification of Diseases 10th Revision (ICD-10-CM) codes previously curated as restrictive (RESPONSE RCT) and extensive (GEMFIN) definitions of TE's within the Diagnosis table in Optum EHR database. |
Not provided
Inclusion Criteria:
Included patients:
HCT ≥ 45% with phlebotomy (last phlebotomy within last 3 months) or Platelet count > 400 x 109/L and presence of palpable splenomegaly (palpable spleen up to 3 months after platelet count).
To identify patients in the RUX group:
- With ≥ 2 prescriptions of RUX in the post-index period.
Exclusion Criteria:
Excluded patients:
- With a MF or AML diagnosis prior to a PV diagnosis.
Not provided
Not provided
PV patients who were resistant to or intolerant of HU in the Optum EHR database between April 2007 and June 2019
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | East Hanover | New Jersey | 07936-1080 | United States |
Not provided
| Label | URL |
|---|---|
| Results for CINC424B3001 from Novartis Clinical Trials Results Database | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D011087 | Polycythemia Vera |
| ID | Term |
|---|---|
| D019046 | Bone Marrow Neoplasms |
| D019337 | Hematologic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C540383 | ruxolitinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Time to first thromboembolic event | Time to first TE in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX was reported. A TE was defined using International Classification of Diseases 9th Revision (ICD-9- CM) and International Classification of Diseases 10th Revision (ICD-10-CM) codes previously curated as restrictive (RESPONSE RCT) and extensive (GEMFIN) definitions of TE's within the Diagnosis table in Optum EHR database. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Incidence rate of phlebotomy procedures | Difference in the incidence rate of phlebotomies in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX was reported. Phlebotomies were defined using Current Procedural Terminology, Fourth Edition (CPT4) codes within the Procedure table in Optum EHR. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Time to first phlebotomy procedure | Time to first phlebotomy in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX was reported. Phlebotomies were defined using Current Procedural Terminology, Fourth Edition (CPT4) codes within the Procedure table in Optum EHR. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Incidence rate of neoplasm transformations | Difference in the incidence rate of neoplasm transformations in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX was reported. A neoplasm transformation was defined as:
| throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Time to first neoplasm transformation | Time to first neoplasm transformation in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX was reported. A neoplasm transformation was defined as:
| throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Treatment patterns: Proportion of patients using different PV-related treatments | Differences in treatment patterns in PV patients resistant to or intolerant of HU treated with BAT compared to those treated with RUX was reported. BAT comprised of multiple therapies for PV including HU, IFN, pegylated IFN (PEG-IFN) and others. These therapies were reported as subcategories under BAT. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Healthcare resource utilization (HCRU): Number of inpatient hospitalizations | Hospitalization was defined as an inpatient stay with a valid visit_ID within the Visit table in Optum EHR. Inpatient hospitalizations were reported as allcause and as PV-specific respectively | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Healthcare resource utilization (HCRU): Number of outpatient visits | Visits with the following visit type: "observation patient" with a valid visit_ID was included as an outpatient visit. Outpatient visits that resulted in an inpatient hospitalization were not included. Outpatient visits were reported as all-cause and as PV-specific respectively. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| Healthcare resource utilization (HCRU): Number of emergency room visits | Visits with the following visit type: "emergency patient" with a valid visit_ID was included as an emergency room visit. Emergency room visits that resulted in an inpatient hospitalization were not included. Emergency room visits were reported as all-cause and as PV-specific respectively. | throughout the study, approximately 13 years (Study period: From 01-Jan-2007 to 30-Jun-2020) |
| D001855 |
| Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D009196 | Myeloproliferative Disorders |